Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)
PHASE2CompletedINTERVENTIONAL
Enrollment
46
Participants
Timeline
Start Date
March 31, 2016
Primary Completion Date
September 30, 2018
Study Completion Date
September 30, 2018
Conditions
Carcinoma, HepatocellularSecondary
Interventions
DRUG
Sorafenib
PO
DRUG
Capecitabine
PO
DRUG
Oxaliplatin
IV
Trial Locations (1)
Unknown
Queen Mary Hospital, Hong Kong
All Listed Sponsors
lead
The University of Hong Kong
OTHER
NCT02716766 - Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC) | Biotech Hunter | Biotech Hunter